Carly Koelsch
Adult Health · Sarasota, FLNPI 1982900098
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $172,103 of the $264,777 with a category attached, or 65.0%. 36 manufacturers reported payments, led by AbbVie at 56.7% of the total. Among adult health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,064 payments — averaging $248.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$150K
- Lilly USA, LLC$95K
- Eli Lilly$10K
- E.r. Squibb & Sons, L.L.C.$2K
- Bristol Myers Squibb$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$971
- plus $5K from 30 others
What the payments were for
- Consulting fees$17,8877%
- Speaking & faculty fees$172,10365%
- Travel & lodging$53,98620%
- Food & beverage$20,7608%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 440 | $150,151 |
| Lilly USA, LLC | 247 | $95,435 |
| Eli Lilly | 28 | $10,289 |
| E.r. Squibb & Sons, L.L.C. | 8 | $1,987 |
| Bristol Myers Squibb | 31 | $1,223 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 58 | $971 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $677 |
| Sanofi | 20 | $548 |
| Johnson & Johnson | 35 | $519 |
| Ironwood Pharmaceuticals, Inc | 20 | $408 |
| Ardelyx, Inc. | 15 | $306 |
| Pfizer | 18 | $304 |
| Nestle Healthcare Nutrition Inc. | 15 | $260 |
| Aimmune Therapeutics, Inc. | 14 | $239 |
| Intercept Pharmaceuticals, Inc. | 10 | $183 |
| Regeneron Healthcare Solutions, Inc. | 7 | $161 |
| Fresenius Kabi USA, LLC | 5 | $125 |
| Phathom Pharmaceuticals, Inc. | 8 | $125 |
| Merck | 7 | $124 |
| Lucid Diagnostics Inc. | 5 | $101 |
| Braintree Laboratories, Inc. | 4 | $76 |
| Ferring Pharmaceuticals Inc. | 5 | $74 |
| Redhill Biopharma Inc. | 5 | $72 |
| Celltrion USA Inc. | 3 | $66 |
| Vivus LLC | 3 | $58 |
| UCB, Inc. | 3 | $51 |
| Ipsen Biopharmaceuticals, Inc | 2 | $39 |
| QOL Medical, LLC | 1 | $31 |
| Organon | 2 | $31 |
| Boston Scientific | 1 | $29 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Novo Nordisk | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Sandoz | 1 | $18 |
| Intra-sana Laboratories | 1 | $17 |
| Evoke Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$264,777 in reported general payments places this provider in the 95th percentile of 2,237 adult health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 19 | $126,373 |
| LinzessLinaclotide | 62 | $50,118 |
| XifaxanRifaximin | 18 | $43,190 |
| Mesalamine | 47 | $27,496 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 118 | $19,006 |
| Omeprazole | 652 | $9,664 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 91 | $5,419 |
| Famotidine | 360 | $4,789 |
| Budesonide DrBudesonide | 39 | $4,023 |
| Dexlansoprazole DrDexlansoprazole | 11 | $3,939 |
| Budesonide EcBudesonide | 15 | $3,377 |
| Pantoprazole Sodium | 153 | $2,656 |
| Sucralfate | 30 | $2,396 |
| Esomeprazole Magnesium | 51 | $1,759 |
| CholestyramineCholestyramine (With Sugar) | 19 | $1,505 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aimmune Therapeutics, Inc.Zenpep | $239 | $126,37319 claims |
| AbbVieLinzess | $150,151 | $50,11862 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $971 | $43,19018 claims |
| Braintree Laboratories, Inc.Sutab | $76 | $19,006118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,237 adult health providers in Florida.
Other adult health in Sarasota
- Robin HammackSarasota$11K
- Patricia PagnottaMaitland$409K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Cynthia OteroMaitland$31K
- Jennifer GodshallTampa$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.